We report that 11 human immunodeficiency virus 1 (HIV-1)-seropositive patients, including three AIDS patients, were able to generate a cellular immune response to the intradermal injection oflow doses (2-10 lag) of recombinant interleukin 2 (rIL-2). A dose-dependent zone of induration appeared at the site of injection, peaked at 24 hr, and was accompanied by the local accumulation of T cells, monocytes, and Langerhans cells. Despite the reductions in the CD41 T-cell counts in the peripheral blood of most patients, CD4' T cells could still be mobilized with rIL-2 hijections into the skin. The total number of immigrant cells was equivalent to those in HIV-1-seronegative patients, although the CD4I/CD8I ratio of the dermal population was reduced. In response to rIL-2, major histocompatibility complex (MHC) class H antigen was expressed on the surface of keratinocytes, Langerhans cells, lymphocytes, and macrophages. In addition, the y interferon (IFN-y)-induced protein IP-10 rapidly appeared in dermal inflammatory cells and keratinocytes. A majority of HIV-1-seropositive patients demonstrated low or absent responses to common skin-test antigens. Those with positive zones of induration were often defective in the cellular expression of the IFN-y-induced MHC class H antigen. The simultaneous administration of rIL-2 and soluble antigen at widely separated cutaneous sites led to an enhancement of skin-test antigen reactivity in seropositive patients. The results suggest that local administration of rIL-2 to seropositive patients may act systemically, stimulating cellular immunity to recall antigens, and thus may be of potential benefit in the defense against opportunistic pathogens encountered in HIV-1 infection.
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Acquired immunodeficiency syndrome (AIDS), an endstage manifestation of human immunodeficiency virus 1 (HIV-1) infection, is characterized by the progressive loss of CD4' T cells (1) and the subsequent defective secretion of lymphokines, including interleukin 2 (IL-2) (2) and y interferon (IFN-y) (3) . This results in impaired mononuclear phagocyte activation and predisposes the patients to a variety of intracellular infections. Asymptomatic HIV-1-seropositive individuals with mild CD4' T-cell deficiencies commonly exhibit cutaneous anergy to skin-test antigens (4) and fail to generate a lymphocyte proliferative response upon stimulation with recall antigens in vitro (5) . The mechanisms contributing to these events are poorly understood.
We have shown (6) that the intradermal administration of low-dose human recombinant IL-2 (rIL-2) can lead to a delayed-type hypersensitivity (DTH) response that is quantitatively and qualitatively similar to that generated by soluble antigens such as purified protein derivative (PPD) of tuberculin. The cutaneous reaction is accompanied by enhanced proliferation of circulating T cells, the generation of cytotoxic T cells, and the disposal of Mycobacterium leprae (7) . We reasoned that rIL-2 may also enhance the cutaneous reactivity of poorly responsive individuals with HIV-1 infection. We now report a comparative study of the effects of local rIL-2 administration in a group of HIV-1-seropositive and -seronegative individuals. We demonstrate that rIL-2 can induce a delayed, cell-mediated immune response in the skin of asymptomatic seropositives and those with AIDS. In addition, rIL-2 can enhance the cutaneous reactivity of seropositive individuals to common skin-test antigens. (3 mm) were taken from the indurated sites primarily on day 2 and/or day 5 after injection. The specimens were processed by paraformaldehyde-lysine-periodate fixation (9) and stored in 25% sucrose/5% (vol/vol) glycerol until sectioned in a cryostat at -20°C. Immunocytochemistry was performed as described (6) . Mouse monoclonal antibodies (mAbs) were used to distinguish specific mononuclear cell types: Leu-2a, Leu-3a, and Leu-4 (anti-CD8, anti-CD4, and anti-CD3 T cells, respectively) and Leu-M5 (anti-CD11c monocyte/macrophage) from Becton Dickinson; OKT6 [anti-CD1 Langerhans cells (LC)] from Ortho Diagnostics; and 9.3F10 [mAb against major histocompatibility complex (MHC) class II antigen] from our laboratory. Biotinylated horse anti-mouse immunoglobulin (Vector Laboratories) was used as the secondary antibody reagent. Rabbit antibody against IP-10 induced by IFN-y (obtained from J. Ravetch, Memorial Sloan-Kettering Cancer Center, NY) followed by biotinylated goat anti-rabbit IgG antibodies were used to identify the IFN-y-inducible protein, IP-10 (10). The sections were evaluated by light microscopy, and enumeration of positive-staining cells was performed at x40 magnification. Photomicrographs were taken with a Nikon Microphot.
METHODS
Peripheral Blood CD4+/CD8 T-Cefl Subset Analysis. Venipuncture was performed prior to the administration of rIL-2 and/or skin test antigens and, in selected patients, after 1, 2, and 4 weeks of injection for routine complete blood cell counts and CD4+/CD8+ T-subset cell analysis.
Statistical Analysis. A paired comparison and Student's t test were used to determine significance (P < 0.01).
RESULTS
Clinical Response to Intradermal rIL-2. The administration of rIL-2 by the intradermal route led to the migration of circulating cells into the injection site and resulted in a zone of erythema and induration, similar to our previous findings in lepromatous leprosy patients (6) . A typical skin response after the injection of 1, 2, and 5 gg of rIL-2 is shown in Fig.   1 . The gross cutaneous changes exhibited by HIV-1-seropositive patients ( Kinetics and dose-response analyses of rIL-2 injection seen in HIV-1-seropositive and -seronegative patients are shown in Fig. 2 . A dose-response correlation following 1-, 2-, and 5-pg injections of rIL-2 was observed. Induration at the injection site was maximal 24 hr after injection and persisted for at least 7 days. Neither parameter of the intradermal response was significantly different in the two groups. Reactions 24 hr after injection were occasionally accompanied by local warmth and pruritus but did not lead to systemic complaints. Peripheral blood CD4' T cells and the CD4+/ CD8' T-cell ratios of injected seropositive patients were not significantly different among those tested 1, 2, and 4 weeks after injection.
Immunohistological Response to rIL-2. Punch biopsies from the center of reactional sites resulting from the intradermal injection of 2 ,ug and 5 ,g of rIL-2 were obtained 2 days and 5 days postinjection, respectively. In both HIV-1-seropositive and -seronegative patients, the mononuclear leukocyte inflammatory infiltrate recruited into the injected site occupied -10-35% of the dermis. Immunostaining indicated that there was a similar distribution of T cells, monocytes/ macrophages, and LC in the dermal infiltrate. T cells were distributed closely in the perivascular regions and diffusely near the epidermis (Fig. 3 A and B) . Appreciable numbers of both CD4+ and CD8+ T cells were found in the skin of both seronegative and seropositive individuals, but the CD4+/ CD8+ T-cell ratios of the dermal infiltrate were quite different. Seropositive patients had mean ratios of <1.0, whereas seronegative patients had mean ratios of 2.0 (Table 2) . These ratios were a reflection ofthe CD4+/CD8+ T-cell ratios ofthe (Table 2) . It is uncertain whether this represented the preferential loss of CD4' T cells and/or the continued recruitment of the CD8' T-cell subset. However, it is clear that seropositive patients with or without AIDS were able to mobilize significant numbers of CD41 T cells into the skin in response to rIL-2.
The number of LC per x40 field was not significantly different in the uninjected skin of HIV-1-seropositive and -seronegative individuals (Table 2 ). After rIL-2 injection, the number of CD1' LC was slightly higher in the thickened epidermis and in the upper dermis (Fig. 4) , but similar numbers were present in both groups. In both cases -30-50% of the LC strongly expressed MHC class II antigen. The injection of rIL-2 modified the phenotype of keratinocytes overlying the injection sites. In both seropositive and seronegative individuals, both MHC class II antigen and IP-10 were expressed on the keratinocytes (Fig. 4 Biopsies taken 2 and 5 days after antigen injection demonstrated a mononuclear cell infiltrate, the extent of which was in proportion to the zones of induration and occupied from 15-50% of the dermis. The infiltrate contained T cells, monocytes/macrophages, and LC, the number and distribution of which were similar to those induced with rIL-2. The CD4+/CD8' T-cell ratios of dermal T cells were again much higher in seronegative individuals ( (Fig. 4) viduals. The results are shown in Table 3 . In the case of tuberculin PPD, an antigen to which only 1 of 20 patients demonstrated any previous sensitization, rIL-2 was without effect. A similar result was obtained with Trichophyton antigen. However, the situation was quite different with Candida antigen, to which most patients were minimally or moderately responsive. Here, there was a significant enhancement in skin-test reactivity in the majority of seropositive patients 1-10 (P < 0.005). The enhancement of skin-test reactivity was based upon comparisons with prior tests done as long as 1 year previously. Patients not receiving rIL-2 failed to show appreciable increments in skin-test reactivity compared with prior testing (patients [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , unless antiviral therapy had been initiated. rIL-2 at a distant site induced more extensive areas of induration as a result of increased cellular infiltration in response to Candida injection. The cellular distribution was similar to that noted with rIL-2 and antigen alone ( Table 2) .
We conclude that low-dose rIL-2 can accentuate the cellmediated immune response to skin-test antigens to which the patient had been sensitized. hIn a paired comparison test, the enhancement of responsiveness in patients 1-10 was significant, with P < 0.005. The changes observed in patients 11-20 were not significant. lAzidothymidine treatment with or without acyclovir therapy was initiated between the two test periods. fashion similar to that observed in the immunodeficiency of lepromatous leprosy (6). Our conclusion is supported by the study of Murray et al. (12) , which provides evidence that the administration of parenteral IL-2 gives rise to large amounts of IFN-y in AIDS patients.
The intensity of the cutaneous response to a skin-test antigen is not as great in HIV-1-seropositive patients as that to recombinant lymphokine. HIV-1-infected patients with prior sensitivity to common antigens may lose or demonstrate fractional reactivity to antigen causing delayed-type hypersensitivity when injected intradermally. In our study this was expressed both as reduced zones of induration and the inability to express MHC class II determinants on the surface of overlying keratinocytes. The expression of IP-10 but not MHC class II antigens on the surface of the keratinocytes suggests that less IFN-y is produced locally in the antigenresponsive site of HIV-infected patients. Since IP-10 can be induced by tumor necrosis factor (TNF) as well as IFN-y (J. V. Ravetch, personal communication), it is possible that TNF is also induced during the local response to antigens in HIV-infected patients. Thus, whereas rIL-2 can stimulate a polyclonal T-cell response with the production of IFN-y and TNF (13, 14) , antigen reactivity recruits only a small percentage of CD4' T cells, the numbers and activity of which are even further compromised by the disease process.
The ability of rIL-2 to generate an enhanced delayed-type cell-mediated response in the poorly reactive HIV-1-seropositive patients deserves further comment. First, it appears that enhancement is dependent upon prior sensitization of patients to the skin-test antigen and is in keeping with our previous studies in leprosy (11) . Second, it is unlikely that sufficient quantities of rIL-2, given at disparate sites, can reach the skin site receiving antigen by a direct vascular or lymphatic route. We suspect that this requires modification of cells passing through the rIL-2 site, their passage back into the circulation and their enhanced homing and reactivity upon entering skin containing an ongoing antigenic challenge. Further studies are required to establish this scenario and to examine the potential of multiple rIL-2 injections and optimal dose range on host cell-mediated reactions. We would hope that this might influence the host's response to secondary intracellular invaders and facilitate defense against opportunistic infections (15) . We caution investigators of the potential hazard of inducing HIV-1 replication in cycling T cells with rIL-2 and suggest the combined usage of azidothymidine (AZT) under these conditions.
